Kymera Therapeutics Announces $65 Million Series B Financing to Advance Pipeline of Targeted Protein Degraders in Oncology and Immunology
Series B financing led by 6 Dimensions Capital, Bessemer Venture Partners, and Pfizer Ventures
Financing to enable the advancement of lead program into clinical development and support the progression of additional programs
CAMBRIDGE, Mass., Nov. 13,... Biopharmaceuticals, Venture Capital, Personnel Kymera Therapeutics, Pegasus
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news